Oct. 8 at 2:37 PM
$QBTS $CABA $FVRR $NVDA
CABA 🧬
This one still has monster upside potential. Analysts have targets in the
$10–
$15 range — that’s 300%–500%+ from here — and some firms have gone as high as
$50/share on long-term pipeline success. It’s pure biotech asymmetry: if the trials hit and funding stays solid, this could go from “forgotten” to “front page” fast. Small float, low expectations, and huge scientific leverage — the setup is perfect for a 3–5× move in a positive readout cycle.
FVRR 💼
Fiverr’s been quietly stabilizing around
$23–24, but the story is far from dead. The gig-economy trend isn’t going away — it’s evolving. With 80–90% gross margins, positive earnings, and over
$700M in cash, Fiverr is built to weather AI shifts and still grow. Analysts see an average target around
$33, which is 40%+ upside, but a full re-rating could double it if growth re-accelerates into 2026.
Bottom line: CABA = high risk, explosive upside.
FVRR = steady growth with 2× potential if sentiment flips.
